Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRTSNASDAQ:EMBCNASDAQ:IRMDNASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRTSAlpha Tau Medical$2.92$2.62$1.75▼$4.39$207.62M0.9247,638 shs54,702 shsEMBCEmbecta$12.00-9.8%$12.45$10.83▼$21.48$697.61M1.24447,584 shs975,119 shsIRMDIradimed$51.79-1.7%$52.10$41.60▼$63.29$658.51M0.9143,568 shs24,445 shsSIBNSI-BONE$18.51+1.0%$14.53$11.70▼$19.16$787.21M0.82368,918 shs840,310 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRTSAlpha Tau Medical0.00%+12.31%+14.96%-6.41%+21.16%EMBCEmbecta-9.77%-5.73%-5.14%-31.11%+16.85%IRMDIradimed-1.67%-3.14%+0.06%-13.90%+19.28%SIBNSI-BONE+0.87%+32.31%+32.97%+8.37%+23.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRTSAlpha Tau Medical2.0483 of 5 stars3.53.00.00.02.21.70.0EMBCEmbecta4.4815 of 5 stars3.23.03.30.02.12.53.8IRMDIradimed4.7511 of 5 stars3.52.02.54.41.93.31.9SIBNSI-BONE3.5176 of 5 stars2.53.00.03.32.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRTSAlpha Tau Medical 3.00Buy$8.00173.97% UpsideEMBCEmbecta 2.33Hold$20.3369.44% UpsideIRMDIradimed 3.00Buy$72.0039.02% UpsideSIBNSI-BONE 3.00Buy$22.5021.56% UpsideCurrent Analyst Ratings BreakdownLatest DRTS, EMBC, IRMD, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025SIBNSI-BONETruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/6/2025SIBNSI-BONECantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/6/2025SIBNSI-BONENeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/29/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/17/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.002/25/2025SIBNSI-BONETruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $22.002/25/2025SIBNSI-BONECantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.002/25/2025SIBNSI-BONENeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $24.002/14/2025IRMDIradimedRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $72.00(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRTSAlpha Tau MedicalN/AN/AN/AN/A$1.21 per shareN/AEMBCEmbecta$1.11B0.63$2.78 per share4.32($13.23) per share-0.91IRMDIradimed$75.15M8.76$1.29 per share40.12$5.66 per share9.15SIBNSI-BONE$176.60M4.46N/AN/A$4.18 per share4.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRTSAlpha Tau Medical-$29.16M-$0.45N/AN/AN/AN/A-38.62%-29.89%5/19/2025 (Estimated)EMBCEmbecta$78.30M$1.0012.003.910.785.25%-19.22%11.92%N/AIRMDIradimed$19.23M$1.5534.5325.90N/A26.26%24.12%21.20%N/ASIBNSI-BONE-$43.34M-$0.64N/AN/AN/A-23.82%-22.51%-16.53%N/ALatest DRTS, EMBC, IRMD, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025DRTSAlpha Tau Medical-$0.14N/AN/AN/AN/AN/A5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/5/2025Q1 2025SIBNSI-BONE-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million3/12/2025Q4 2024DRTSAlpha Tau Medical-$0.13-$0.13N/A-$0.13N/AN/A2/24/2025Q4 2024SIBNSI-BONE-$0.16-$0.11+$0.05-$0.11$48.87 million$49.00 million2/13/2025Q4 2024IRMDIradimed$0.45$0.40-$0.05$0.40$19.09 million$19.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRTSAlpha Tau MedicalN/AN/AN/AN/AN/AEMBCEmbecta$0.605.00%N/A60.00%N/AIRMDIradimed$0.681.31%N/A43.87%1 YearsSIBNSI-BONEN/AN/AN/AN/AN/ALatest DRTS, EMBC, IRMD, and SIBN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/9/2025EMBCEmbectaquarterly$0.154.51%5/28/20256/13/20255/5/2025IRMDIradimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRTSAlpha Tau Medical0.0810.99N/AEMBCEmbectaN/A2.241.67IRMDIradimedN/A9.217.82SIBNSI-BONE0.228.257.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRTSAlpha Tau Medical2.65%EMBCEmbecta93.83%IRMDIradimed92.34%SIBNSI-BONE98.11%Insider OwnershipCompanyInsider OwnershipDRTSAlpha Tau Medical39.50%EMBCEmbecta0.42%IRMDIradimed37.10%SIBNSI-BONE4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRTSAlpha Tau Medical8070.38 million42.30 millionNo DataEMBCEmbecta1,90058.13 million57.89 millionOptionableIRMDIradimed11012.72 million7.97 millionOptionableSIBNSI-BONE35042.53 million40.30 millionOptionableDRTS, EMBC, IRMD, and SIBN HeadlinesRecent News About These CompaniesSI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 4,937 SharesMay 10 at 6:36 AM | insidertrades.comEarnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsMay 9 at 12:28 PM | finance.yahoo.comWall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a BetMay 8 at 11:02 AM | zacks.comSI-BONE (NASDAQ:SIBN) Shares Gap Up After Strong EarningsMay 8 at 10:21 AM | marketbeat.comSI-BONE's (SIBN) "Overweight" Rating Reiterated at Cantor FitzgeraldMay 8 at 9:25 AM | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for SI-BONE (NASDAQ:SIBN)May 8 at 8:31 AM | marketbeat.comTudor Investment Corp ET AL Has $1.25 Million Holdings in SI-BONE, Inc. (NASDAQ:SIBN)May 8 at 4:18 AM | marketbeat.comSI-BONE (NASDAQ:SIBN) Shares Gap Up Following Earnings BeatMay 8 at 1:25 AM | americanbankingnews.comSI-BONE Inc. Q1 Loss Decreases, Beats EstimatesMay 7 at 6:54 PM | nasdaq.comSI-BONE (NASDAQ:SIBN) Announces Earnings ResultsMay 7 at 4:44 PM | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Brown Advisory Inc.May 7 at 6:16 AM | marketbeat.comSI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025May 6, 2025 | globenewswire.comBellevue Group AG Has $12.35 Million Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)May 6, 2025 | marketbeat.comRaymond James Financial Inc. Invests $1.23 Million in SI-BONE, Inc. (NASDAQ:SIBN)May 6, 2025 | marketbeat.comSI-BONE, Inc. Reports Strong Q1 2025 GrowthMay 6, 2025 | tipranks.comSI-BONE, Inc. (SIBN) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comSi-Bone (SIBN) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2025 | zacks.comSI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 GuidanceMay 5, 2025 | globenewswire.comCANADA LIFE ASSURANCE Co Has $54,000 Position in SI-BONE, Inc. (NASDAQ:SIBN)May 3, 2025 | marketbeat.comSI-BONE (SIBN) to Release Quarterly Earnings on MondayMay 3, 2025 | americanbankingnews.comFirst Light Asset Management LLC Sells 389,233 Shares of SI-BONE, Inc. (NASDAQ:SIBN)April 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRTS, EMBC, IRMD, and SIBN Company DescriptionsAlpha Tau Medical NASDAQ:DRTS$2.92 0.00 (0.00%) As of 05/9/2025 03:51 PM EasternAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Embecta NASDAQ:EMBC$12.00 -1.30 (-9.77%) As of 05/9/2025 03:58 PM EasternEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Iradimed NASDAQ:IRMD$51.79 -0.88 (-1.67%) As of 05/9/2025 03:52 PM EasternIRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.SI-BONE NASDAQ:SIBN$18.51 +0.18 (+0.98%) As of 05/9/2025 03:57 PM EasternSI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
